MUDr. Petr Potměšil, Ph.D.












            ******************************************************************************************

            *
            ******************************************************************************************
            <div class="skolitel"></div>

            Department of Pharmacology 3FM CU
            https://www.lf3.cuni.cz/3LF-400.html [ URL "https://www.lf3.cuni.cz/3LF-400.html"]


            Topic title
            Pharmacokinetics
            Pharmacovigilance in oncology





            *=========================================================================================
            * Description of scientific activity

            *=========================================================================================
            Pharmacokinetics - Use of software MW-Pharm in therapeutic monitoring of levels of antidep
            antipsychotic drugs


            Pharmacovigilance in oncology - Incidence of serious or unexpected adverse events during t
            with capecitabine or 5-fluorouracil in patients screened for the presence of complete dihy

            dehydrogenase deficiency




            *=========================================================================================
            * Selected publications

            *=========================================================================================
            P. Potměšil and R. Straková. Drug induced liver injury after switching from tamoxifen to a
            patient after breast cancer being treated for hypertension and diabetes. Therapeutic Advan

            Disease 2020; 11: 1-11.

            P. Potměšil. What combinations of agomelatine with other antidepressants could be successf

            treatment of major depressive disorder or anxiety disorders in clinical practice. Therapeu
            Psychopharmacology 2019; 9: 1-11.


            M. Kopeček and P. Potměšil. How long does the pharmacokinetic interaction between carbamaz
            quetiapine last after carbamazepine withdrawal? Neuro Endocrinol Lett. 2017; 38: 475-478.




            *=========================================================================================

            * Selected or ongoing grants/clinical studies
            *=========================================================================================
            2020-2026: TheraLymph –Gene Therapy to restore lymphatic flow lymphedema, H2020 SC1-BHC-07

            874708
            2021-2024: Novel approaches to enhance insulin-sensitizing effects of exercise: targeting 
            ETAPA; Czech Health Research Council project NU21-01-00469

            2019 - 2022: Pancreatic cancer: metabolic derangements assiocated with insulin resistence 
            Health Research Council project NV19-01-00101, Co-PI: Lenka Rossmeislova